We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 105

Product Liability eNewsletter - Summer 2016
  • Thompson Hine LLP
  • USA, Ireland
  • July 25 2016

The Food and Drug Administration’s (FDA) June 17, 2015 final determination regarding partially hydrogenated oils (PHOs), the primary source of trans


US FDA updates for Irish and Northern Irish companies
  • Arnall Golden Gregory LLP
  • USA, Ireland
  • June 26 2015

AGG produces a monthly update of legal and regulatory issues that affect the FDA-regulated community, including regular updates on legislative


User fees for generic drugs - what are the issues?
  • Sheppard Mullin Richter & Hampton LLP
  • USA, Ireland
  • August 30 2010

On August 9, 2010, the Food and Drug Administration ("FDA") published a notice announcing a public meeting to be held September 17, 2010, "to gather stakeholder input on the development of a generic drug user fee program."


Lauren F. Myers
  • Kelley Drye & Warren LLP






Ilunga L. Kalala
  • Kelley Drye & Warren LLP